The biotechnology industry position survey provides an annual snapshot of the industry's views on key issues. The key findings were:
1) Sentiment in the industry remains positive, with 82% of respondents expecting business growth in the coming year and 68% characterizing 2011 as a good year.
2) Most companies plan to increase staffing levels, primarily in sales/marketing and scientific roles.
3) Despite 54% raising capital in 2011, funding remains a challenge with 34% having less than 12 months of cash.
4) The majority see the new R&D tax incentive as positively impacting their business, though over half have not sought advice on it.
Trends in Global Medical Device OEM Strategies and Issues for the Medical Dev...Tony Freeman
Presented at the February, 2013 mdmX Conference, Manning Advisors' Tony Freeman reviews issues facing the largest medical device manufacturers and implications for their supply chain.
Lifesciences IT - 2011 YearbookSummaryGBI Research's research, 'Lifesciences IT - 2011 Yearbook" provides key data, information and analysis on Lifesciences \IT that is being implemented by pharmaceutical companies. GBI Research expects that information technology (IT) in the lifesciences industry will become a trendsetter, helping pharmaceutical companies mitigate current and evolving industry challenges. IT solutions utilized in the value chain of pharmaceutical companies help them to operate effectively and efficiently. GBI expects an increase in the adoption of IT by pharmaceutical companies looking to remain competitive in the market place. The Lifesciences industry is pressurized by various challenges such as declining Return on Investment (ROI) on R&D investments, entry of generics and layoffs. These factors are responsible for the lifesciences companies to invest in information technology solutions. Pharmaceutical companies have found that experimental techniques are costly, time-consuming, and involve the use of large numbers of animals for testing and are adapting to computerized combinatorial chemistry applications. Pharmaceutical Companies are increasingly adopting e-clinical trial solutions in the drug development phase. Cutting down clinical trial cost is the driving motivation for the adoption of e-clinical trial solutions. Services offered by IT companies in clinical data management are costly but have been proved to save cost for the companies in the long run. CTMS and EDC will attract the highest investments in the future followed by data mining, electronic submission tools and RFID. Outsourcing helps a pharmaceutical company to reduce costs by 30-35% and this is one of the main reasons why pharmaceutical companies outsource non-core R&D operational work to IT companies. When selecting a country to outsource clinical data management work, building the required competencies to tackle client requirements has gained a higher importance than the cost advantage it provides. The predictive analytics helps a company view beyond the sales volume in to real time prescribing patterns, as a behavior of continuum. This also helps the company to follow the evolving niche buster model. Many pharmaceutical companies have increased satisfaction levels from their customers in 2008. In 2004, 50% of the physicians were satisfied on the current number of calls. However, satisfaction levels have increased in 2008 with more than 57% of the physicians in the US satisfied with the current number of calls. The increase in satisfaction levels was directly proportional to the decrease of sales force in the US. It is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research's team of industry experts.ScopeThe scope of this report includes - - Analysis of the leading segments in the Lifesciences IT market - Key drivers and barriers that have a significant impact on the Lifesciences IT market. - Competitive benchmarking of leading companies in the market. - Key M&A activities and strategic partnership deals that have taken place in 2009.- Inputs for customized IT solution based on business situation.Reasons to buyThe report will enhance your decision making capability. It will provide you with - - Align your product portfolio to the markets with high growth potential.- Develop market-entry and market expansion strategies by identifying the leading segments poised for strong growth.- Device better strategies through the understanding of key drivers and barriers in the market.- Develop key strategic initiatives by understanding the key focus of leading companies.- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.
BioCentury BayHelix China healthcare Summit 2016 - McKinsey report _building...Franck Le Deu
In this report prepared in the context of the BioCentury China Summit, we provide an overview of the latest trends impacting China healthcare and the biopharma market, including the CFDA reform.
Trends in Global Medical Device OEM Strategies and Issues for the Medical Dev...Tony Freeman
Presented at the February, 2013 mdmX Conference, Manning Advisors' Tony Freeman reviews issues facing the largest medical device manufacturers and implications for their supply chain.
Lifesciences IT - 2011 YearbookSummaryGBI Research's research, 'Lifesciences IT - 2011 Yearbook" provides key data, information and analysis on Lifesciences \IT that is being implemented by pharmaceutical companies. GBI Research expects that information technology (IT) in the lifesciences industry will become a trendsetter, helping pharmaceutical companies mitigate current and evolving industry challenges. IT solutions utilized in the value chain of pharmaceutical companies help them to operate effectively and efficiently. GBI expects an increase in the adoption of IT by pharmaceutical companies looking to remain competitive in the market place. The Lifesciences industry is pressurized by various challenges such as declining Return on Investment (ROI) on R&D investments, entry of generics and layoffs. These factors are responsible for the lifesciences companies to invest in information technology solutions. Pharmaceutical companies have found that experimental techniques are costly, time-consuming, and involve the use of large numbers of animals for testing and are adapting to computerized combinatorial chemistry applications. Pharmaceutical Companies are increasingly adopting e-clinical trial solutions in the drug development phase. Cutting down clinical trial cost is the driving motivation for the adoption of e-clinical trial solutions. Services offered by IT companies in clinical data management are costly but have been proved to save cost for the companies in the long run. CTMS and EDC will attract the highest investments in the future followed by data mining, electronic submission tools and RFID. Outsourcing helps a pharmaceutical company to reduce costs by 30-35% and this is one of the main reasons why pharmaceutical companies outsource non-core R&D operational work to IT companies. When selecting a country to outsource clinical data management work, building the required competencies to tackle client requirements has gained a higher importance than the cost advantage it provides. The predictive analytics helps a company view beyond the sales volume in to real time prescribing patterns, as a behavior of continuum. This also helps the company to follow the evolving niche buster model. Many pharmaceutical companies have increased satisfaction levels from their customers in 2008. In 2004, 50% of the physicians were satisfied on the current number of calls. However, satisfaction levels have increased in 2008 with more than 57% of the physicians in the US satisfied with the current number of calls. The increase in satisfaction levels was directly proportional to the decrease of sales force in the US. It is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research's team of industry experts.ScopeThe scope of this report includes - - Analysis of the leading segments in the Lifesciences IT market - Key drivers and barriers that have a significant impact on the Lifesciences IT market. - Competitive benchmarking of leading companies in the market. - Key M&A activities and strategic partnership deals that have taken place in 2009.- Inputs for customized IT solution based on business situation.Reasons to buyThe report will enhance your decision making capability. It will provide you with - - Align your product portfolio to the markets with high growth potential.- Develop market-entry and market expansion strategies by identifying the leading segments poised for strong growth.- Device better strategies through the understanding of key drivers and barriers in the market.- Develop key strategic initiatives by understanding the key focus of leading companies.- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.
BioCentury BayHelix China healthcare Summit 2016 - McKinsey report _building...Franck Le Deu
In this report prepared in the context of the BioCentury China Summit, we provide an overview of the latest trends impacting China healthcare and the biopharma market, including the CFDA reform.
Environmental Cost Disclosure and Corporate Performance of Quoted Foods and B...YogeshIJTSRD
This study determined the effect of Environmental Cost Disclosure and Performance of Quoted foods and beverages firms in Nigeria. Ex post facto research design and content analysis was adapted for the study. Sample size of nine 9 Foods and Beverage firms were used from twelve 12 Foods and Beverage firms. Data for the study were collected from the audited accounts of the sampled Food and Beverage firms in Nigeria from 2010 to 2019. Formulated hypotheses were tested using multiple linear regression analysis with the aid of E view 9.0. Environmental restoration cost and environmental pollution control cost has no significant effect on firm’s return on assets. Therefore, recommended that the implementation of greener technique, that is, environmental restoration enhanced mark up to protect the environment and increased firms’ return on assets. Egbunike, Patrick A. | Odumodu, Mary Theresa C. "Environmental Cost Disclosure and Corporate Performance of Quoted Foods and Beverages Firms in Nigeria" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-5 | Issue-5 , August 2021, URL: https://www.ijtsrd.com/papers/ijtsrd44971.pdf Paper URL: https://www.ijtsrd.com/management/organizational-behaviour/44971/environmental-cost-disclosure-and-corporate-performance-of-quoted-foods-and-beverages-firms-in-nigeria/egbunike-patrick-a
OECD expert workshop on the measurement of public procurement of innovation. ...STIEAS
OECD expert workshop on the measurement of public procurement of innovation. "Public Procurement for Innovation: Measurement issues and Comments", presentation by Lee Woosung
Sustainability Reporting and Corporate Performance of Conglomerate and Indust...YogeshIJTSRD
Sustainability reporting remains a continuing concern as stakeholders demand for firms to be more socially, environmentally, and economically responsible continues to increase especially in developing countries like Nigeria. Thus, the study examined the effect of sustainability reporting disclosures of conglomerate and industrial goods manufacturing firms in Nigeria on their market share and return on assets. The study employed an ex post facto research design as data were obtained from the annual report of firms for a period of ten years 2010 2019 . Multiple regression analytical tools with the help of SPSS version 23 were used in analyzing the data for 16 conglomerate and industrial goods firms selected using the purposive sampling technique. The findings revealed that sustainability reporting has positive effect on market share and return on assets of firms studied. Based on the findings, it was concluded that sustainability reporting affects the performance of manufacturing firms and it was recommended that standard setters and government should develop a standard mandatory disclosure framework to ensure consistency and uniformity in reporting and also, companies are encouraged to disclose their economic, social and environmental information all geared to help stakeholders make informed decision. Okoye, Ezinne Chimaram | Ezeagba, Charles Emenike "Sustainability Reporting and Corporate Performance of Conglomerate and Industrial Goods Firms in Nigeria: An Empirical Study" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-5 | Issue-5 , August 2021, URL: https://www.ijtsrd.com/papers/ijtsrd44977.pdf Paper URL: https://www.ijtsrd.com/management/accounting-and-finance/44977/sustainability-reporting-and-corporate-performance-of-conglomerate-and-industrial-goods-firms-in-nigeria-an-empirical-study/okoye-ezinne-chimaram
Bringing Your Supplements, Medical Foods and Pharmaceutical Drugs to MarketNutrcapnetwork
With companies in nutrition and health & wellness making crucial product development and marketing decisions, a clear picture of regulatory tracks for supplements, medical foods and drugs is essential. Co-hosted by Nutritional Capital Network and Todd Harrison, Co-Chair, Food, Dietary Supplements and Cosmetics Practice of Venable LLP, NCN's law firm sponsor.
The insights driving superior healthcare outcomes in Asia Pacific.
Asia-Pacific Insight Magazine brings together IMS Health experts from across the region, delivering fresh perspectives on how to navigate through the challenges and opportunities in Asia-Pacific pharmaceutical market.
PharmAsia Summit2013 report "In search of new growth models for Big Pharma in...Franck Le Deu
Our latest report on the dynamics of the China pharmaceuticals market. Developed with BayHelix and Elsevier. We discuss the recent trends impacting the market and their implications on Pharma MNCs strategies and business models.
John Grubb, Managing Partner of Sterling Rice Group, joins Principals of Nutrition Capital Network to discuss the elements of branding: premise, product, positioning construct, channel strategy and in-market voice.
The ten predictions for 2020
1. Health consumers in 2020
Informed and demanding patients are now partners in their own healthcare
2. Health care delivery systems in 2020
The era of digitised medicine - new business models drive new ideas
3. Wearables and mHealth applications in 2020
Measuring quality of life not just clinical indicators
4. Big Data in 2020
Health data is pervasive – requiring new tools and provider models
5. Regulation in 2020
Regulations reflect the convergence of technology and science
6. Research and Development in 2020
The networked laboratory - partnerships and big data amidst new scrutiny
7. The pharmaceutical commercial model in 2020
Local is important but with a shift from volume to value
8. The pharmaceutical enterprise configuration - the back office in 2020
Single, global and responsible for insight enablement
9. New business models in emerging markets in 2020
Still emerging, but full of creativity for the world
10. Impact of behaviours on corporate reputation in 2020
A new dawn of trust
Environmental Cost Disclosure and Corporate Performance of Quoted Foods and B...YogeshIJTSRD
This study determined the effect of Environmental Cost Disclosure and Performance of Quoted foods and beverages firms in Nigeria. Ex post facto research design and content analysis was adapted for the study. Sample size of nine 9 Foods and Beverage firms were used from twelve 12 Foods and Beverage firms. Data for the study were collected from the audited accounts of the sampled Food and Beverage firms in Nigeria from 2010 to 2019. Formulated hypotheses were tested using multiple linear regression analysis with the aid of E view 9.0. Environmental restoration cost and environmental pollution control cost has no significant effect on firm’s return on assets. Therefore, recommended that the implementation of greener technique, that is, environmental restoration enhanced mark up to protect the environment and increased firms’ return on assets. Egbunike, Patrick A. | Odumodu, Mary Theresa C. "Environmental Cost Disclosure and Corporate Performance of Quoted Foods and Beverages Firms in Nigeria" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-5 | Issue-5 , August 2021, URL: https://www.ijtsrd.com/papers/ijtsrd44971.pdf Paper URL: https://www.ijtsrd.com/management/organizational-behaviour/44971/environmental-cost-disclosure-and-corporate-performance-of-quoted-foods-and-beverages-firms-in-nigeria/egbunike-patrick-a
OECD expert workshop on the measurement of public procurement of innovation. ...STIEAS
OECD expert workshop on the measurement of public procurement of innovation. "Public Procurement for Innovation: Measurement issues and Comments", presentation by Lee Woosung
Sustainability Reporting and Corporate Performance of Conglomerate and Indust...YogeshIJTSRD
Sustainability reporting remains a continuing concern as stakeholders demand for firms to be more socially, environmentally, and economically responsible continues to increase especially in developing countries like Nigeria. Thus, the study examined the effect of sustainability reporting disclosures of conglomerate and industrial goods manufacturing firms in Nigeria on their market share and return on assets. The study employed an ex post facto research design as data were obtained from the annual report of firms for a period of ten years 2010 2019 . Multiple regression analytical tools with the help of SPSS version 23 were used in analyzing the data for 16 conglomerate and industrial goods firms selected using the purposive sampling technique. The findings revealed that sustainability reporting has positive effect on market share and return on assets of firms studied. Based on the findings, it was concluded that sustainability reporting affects the performance of manufacturing firms and it was recommended that standard setters and government should develop a standard mandatory disclosure framework to ensure consistency and uniformity in reporting and also, companies are encouraged to disclose their economic, social and environmental information all geared to help stakeholders make informed decision. Okoye, Ezinne Chimaram | Ezeagba, Charles Emenike "Sustainability Reporting and Corporate Performance of Conglomerate and Industrial Goods Firms in Nigeria: An Empirical Study" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-5 | Issue-5 , August 2021, URL: https://www.ijtsrd.com/papers/ijtsrd44977.pdf Paper URL: https://www.ijtsrd.com/management/accounting-and-finance/44977/sustainability-reporting-and-corporate-performance-of-conglomerate-and-industrial-goods-firms-in-nigeria-an-empirical-study/okoye-ezinne-chimaram
Bringing Your Supplements, Medical Foods and Pharmaceutical Drugs to MarketNutrcapnetwork
With companies in nutrition and health & wellness making crucial product development and marketing decisions, a clear picture of regulatory tracks for supplements, medical foods and drugs is essential. Co-hosted by Nutritional Capital Network and Todd Harrison, Co-Chair, Food, Dietary Supplements and Cosmetics Practice of Venable LLP, NCN's law firm sponsor.
The insights driving superior healthcare outcomes in Asia Pacific.
Asia-Pacific Insight Magazine brings together IMS Health experts from across the region, delivering fresh perspectives on how to navigate through the challenges and opportunities in Asia-Pacific pharmaceutical market.
PharmAsia Summit2013 report "In search of new growth models for Big Pharma in...Franck Le Deu
Our latest report on the dynamics of the China pharmaceuticals market. Developed with BayHelix and Elsevier. We discuss the recent trends impacting the market and their implications on Pharma MNCs strategies and business models.
John Grubb, Managing Partner of Sterling Rice Group, joins Principals of Nutrition Capital Network to discuss the elements of branding: premise, product, positioning construct, channel strategy and in-market voice.
The ten predictions for 2020
1. Health consumers in 2020
Informed and demanding patients are now partners in their own healthcare
2. Health care delivery systems in 2020
The era of digitised medicine - new business models drive new ideas
3. Wearables and mHealth applications in 2020
Measuring quality of life not just clinical indicators
4. Big Data in 2020
Health data is pervasive – requiring new tools and provider models
5. Regulation in 2020
Regulations reflect the convergence of technology and science
6. Research and Development in 2020
The networked laboratory - partnerships and big data amidst new scrutiny
7. The pharmaceutical commercial model in 2020
Local is important but with a shift from volume to value
8. The pharmaceutical enterprise configuration - the back office in 2020
Single, global and responsible for insight enablement
9. New business models in emerging markets in 2020
Still emerging, but full of creativity for the world
10. Impact of behaviours on corporate reputation in 2020
A new dawn of trust
Zmiany te to dobra wiadomość dla przedsiębiorstw, bowiem nieco odciążają je od części zbędnej „papierologii”. Liberalizują obowiązki pracodawcy związane z ustalaniem regulaminów oraz świadectw pracy, jak również wydłużają terminy na występowanie pracowników z roszczeniami ze stosunku pracy. W niniejszym raporcie pomagamy zrozumieć szczegóły dotyczące tych zmian i przygotować firmę do ich stosowania.
Developing a Globally Competitive Singaporean Life Science IndustryXiangQian (XQ) Lin
This paper seeks to explore the potential opportunities which Singapore can explore to fulfill its key economic objectives amidst global and regional developments within the life science industry and in the process develop Singapore-domiciled companies into viable players on the global stage.
Trailblazing scientists who are the backbone of our industry. These are the people that discover the molecules and develop the medicines to tackle the toughest diseases we face in society.
A complete guide to learn information and trends about the healthcare industry. Details are shared from both Global and APAC perspective. It is carefully drafted to give continuous information, particularly when it comes to numbers.
Produkcja prawa zwolniła, ale nadal przytłacza firmyGrant Thornton
W 2017 r. w życie weszło 27,1 tys. stron nowych aktów prawnych, czyli o 15 proc. mniej niż rok wcześniej. Na tym jednak dobre wiadomości się kończą – wynika z raportu Grant Thornton.
Stabilność prawa to jeden z warunków długotrwałego rozwoju gospodarczego. Nadmierna zmienność regulacji nie tylko utrudnia firmom działalność, naraża je na kary i grzywny, ale też zniechęca przedsiębiorców do podejmowania inwestycji. Żeby mierzyć skalę zmienności prawa, uruchomiliśmy trzy lata temu swój „Barometr otoczenia prawnego w polskiej gospodarce”, czyli projekt badawczy, który na konkretnych liczbach pokazuje, jak dużo prawa produkuje się w Polsce w danym okresie.
10 najważniejszych zmian w podatkach ostatnich dwóch latGrant Thornton
Ranking najważniejszych z punktu widzenia podatnika zmian w przepisach podatkowych, które weszły w życie przez pierwsze dwa lata obecnej kadencji rządu
Polskie firmy nie chcą rozwijać nowych produktów Grant Thornton
Firma, aby się rozwijać, musi stale wprowadzać na rynek nowe produkty i usługi. W innym wypadku zostanie wyprzedzona przez bardziej dynamiczną konkurencję.
Jak pod tym względem wypadają obecnie polskie firmy? Zapraszamy do zapoznania się z wynikami badania przeprowadzonego przez Grant Thornton wśród średnich i dużych przedsiębiorstw z 33 krajów świata
Z przyjemnością prezentujemy kolejną edycję „Purpurowego Informatora”, czyli cyklu analiz, w którym omawiamy ważne dla przedsiębiorców kwestie prawne, księgowe i kadrowe.
Tym razem tematem naszego cyklu jest Jednolity Plik Kontrolny (JPK). Co to jest? Do czego służy? Jacy podatnicy mają obowiązek przekazywania JPK? Odpowiedzi na te i inne pytania znajdą Państwo w poniższym materiale.
Zmiany w przepisach o ochronie danych osobowychGrant Thornton
W maju 2018 roku zacznie obowiązywać unijne rozporządzenie o ochronie danych osobowych. Nowe przepisy będą dotyczyć wszystkich podmiotów, które na terenie UE przetwarzają dane w sposób zautomatyzowany. Warto zapoznać się z najważniejszymi zmianami zachodzącymi w rozporządzeniu i rozpocząć przygotowania już teraz.
Rekordowe wyniki rynku Catalyst w 2016 rokuGrant Thornton
Wartość nieskarbowych instrumentów dłużnych notowanych na Catalyst osiągnęła na koniec czwartego kwartału 2016 roku 81,8 mld zł, co było najwyższym wynikiem od momentu powstania rynku Catalyst – wynika z przygotowanego przez nas raportu pod patronatem Giełdy Papierów Wartościowych w Warszawie.
Festiwalowe szaleństwo na studencką kieszeńGrant Thornton
Średni koszt wyjazdu na festiwal muzyczny latem 2017 r. to 1530,04 zł – wynika z naszego raportu. Spośród największych europejskich festiwali najtaniej spędzisz czas na Coulors of Ostrava. Najbardziej ceną kuszą jednak polskie imprezy, zwłaszcza Przystanek Woodstock.
Grant Thornton’s transactional teams advised on a number of high profile deals throughout Europe in 2016, driving strong outcomes through highly experienced and internationally connected professionals. Grant Thornton’s success was reflected in the number two position (by average deal value) in the ranking of the top ten M&A advisors in Europe.
Z przyjemnością prezentujemy kolejną edycję „Purpurowego Informatora”, czyli cyklu analiz, w którym omawiamy ważne dla przedsiębiorców kwestie prawne, księgowe i kadrowe. Tym razem tematem naszego cyklu jest pakiet zmian w ustawie o rachunkowości, które obowiązują od 2016 roku.
Wpływy transferowe klubów piłkarskiej Ekstraklasy osiągnęły w sezonie 2016/2017 wartość 33,5 mln EUR – wynika z Grant Thornton. To najlepszy wynik w historii.
Tata Group Dials Taiwan for Its Chipmaking Ambition in Gujarat’s DholeraAvirahi City Dholera
The Tata Group, a titan of Indian industry, is making waves with its advanced talks with Taiwanese chipmakers Powerchip Semiconductor Manufacturing Corporation (PSMC) and UMC Group. The goal? Establishing a cutting-edge semiconductor fabrication unit (fab) in Dholera, Gujarat. This isn’t just any project; it’s a potential game changer for India’s chipmaking aspirations and a boon for investors seeking promising residential projects in dholera sir.
Visit : https://www.avirahi.com/blog/tata-group-dials-taiwan-for-its-chipmaking-ambition-in-gujarats-dholera/
buy old yahoo accounts buy yahoo accountsSusan Laney
As a business owner, I understand the importance of having a strong online presence and leveraging various digital platforms to reach and engage with your target audience. One often overlooked yet highly valuable asset in this regard is the humble Yahoo account. While many may perceive Yahoo as a relic of the past, the truth is that these accounts still hold immense potential for businesses of all sizes.
Digital Transformation and IT Strategy Toolkit and TemplatesAurelien Domont, MBA
This Digital Transformation and IT Strategy Toolkit was created by ex-McKinsey, Deloitte and BCG Management Consultants, after more than 5,000 hours of work. It is considered the world's best & most comprehensive Digital Transformation and IT Strategy Toolkit. It includes all the Frameworks, Best Practices & Templates required to successfully undertake the Digital Transformation of your organization and define a robust IT Strategy.
Editable Toolkit to help you reuse our content: 700 Powerpoint slides | 35 Excel sheets | 84 minutes of Video training
This PowerPoint presentation is only a small preview of our Toolkits. For more details, visit www.domontconsulting.com
3.0 Project 2_ Developing My Brand Identity Kit.pptxtanyjahb
A personal brand exploration presentation summarizes an individual's unique qualities and goals, covering strengths, values, passions, and target audience. It helps individuals understand what makes them stand out, their desired image, and how they aim to achieve it.
An introduction to the cryptocurrency investment platform Binance Savings.Any kyc Account
Learn how to use Binance Savings to expand your bitcoin holdings. Discover how to maximize your earnings on one of the most reliable cryptocurrency exchange platforms, as well as how to earn interest on your cryptocurrency holdings and the various savings choices available.
Implicitly or explicitly all competing businesses employ a strategy to select a mix
of marketing resources. Formulating such competitive strategies fundamentally
involves recognizing relationships between elements of the marketing mix (e.g.,
price and product quality), as well as assessing competitive and market conditions
(i.e., industry structure in the language of economics).
Building Your Employer Brand with Social MediaLuanWise
Presented at The Global HR Summit, 6th June 2024
In this keynote, Luan Wise will provide invaluable insights to elevate your employer brand on social media platforms including LinkedIn, Facebook, Instagram, X (formerly Twitter) and TikTok. You'll learn how compelling content can authentically showcase your company culture, values, and employee experiences to support your talent acquisition and retention objectives. Additionally, you'll understand the power of employee advocacy to amplify reach and engagement – helping to position your organization as an employer of choice in today's competitive talent landscape.
Navigating the world of forex trading can be challenging, especially for beginners. To help you make an informed decision, we have comprehensively compared the best forex brokers in India for 2024. This article, reviewed by Top Forex Brokers Review, will cover featured award winners, the best forex brokers, featured offers, the best copy trading platforms, the best forex brokers for beginners, the best MetaTrader brokers, and recently updated reviews. We will focus on FP Markets, Black Bull, EightCap, IC Markets, and Octa.
Best practices for project execution and deliveryCLIVE MINCHIN
A select set of project management best practices to keep your project on-track, on-cost and aligned to scope. Many firms have don't have the necessary skills, diligence, methods and oversight of their projects; this leads to slippage, higher costs and longer timeframes. Often firms have a history of projects that simply failed to move the needle. These best practices will help your firm avoid these pitfalls but they require fortitude to apply.
How to Implement a Real Estate CRM SoftwareSalesTown
To implement a CRM for real estate, set clear goals, choose a CRM with key real estate features, and customize it to your needs. Migrate your data, train your team, and use automation to save time. Monitor performance, ensure data security, and use the CRM to enhance marketing. Regularly check its effectiveness to improve your business.
In the Adani-Hindenburg case, what is SEBI investigating.pptxAdani case
Adani SEBI investigation revealed that the latter had sought information from five foreign jurisdictions concerning the holdings of the firm’s foreign portfolio investors (FPIs) in relation to the alleged violations of the MPS Regulations. Nevertheless, the economic interest of the twelve FPIs based in tax haven jurisdictions still needs to be determined. The Adani Group firms classed these FPIs as public shareholders. According to Hindenburg, FPIs were used to get around regulatory standards.
FIA officials brutally tortured innocent and snatched 200 Bitcoins of worth 4...jamalseoexpert1978
Farman Ayaz Khattak and Ehtesham Matloob are government officials in CTW Counter terrorism wing Islamabad, in Federal Investigation Agency FIA Headquarters. CTW and FIA kidnapped crypto currency owner from Islamabad and snatched 200 Bitcoins those worth of 4 billion rupees in Pakistan currency. There is not Cryptocurrency Regulations in Pakistan & CTW is official dacoit and stealing digital assets from the innocent crypto holders and making fake cases of terrorism to keep them silent.
2. The Biotechnology Industry Position Survey
provides us with a comprehensive annual
industry snapshot, direct from the industry’s
leaders, based on experience, business knowledge
and political insights.
Dr Anna Lavelle
CEO AusBiotech Ltd
We are proud to support the Australian biotechnology
industry with this survey. The survey is an important
tool to understand the issues and assist in laying a
foundation to secure greater support for the industry.
Michael Cunningham
National Head of Life Sciences
Grant Thornton Australia Ltd
Contents
Key findings of the survey 02 Demographics 10
Background 03 Survey participants 11
Survey findings - Sentiment 04 About AusBiotech 12
Survey findings - Funding 06 About Grant Thornton 13
Survey findings - Government policy 08
Biotechnology Industry Position Survey 01
3. Key findings of the survey
Welcome to the annual Biotechnology Industry
Position Survey. This research has been conducted
as part of both AusBiotech and Grant Thornton’s
ongoing commitment to the biotechnology industry.
• The bullish sentiment reported in 2011 • The passage of the Research and Development
continues with 82% (75%: 2011) of respondents (R&D) Tax Incentive legislation was a
expecting their business to grow in the coming significant event with the majority (65%) of
year, while 68% characterised 2011 as a good or companies indicating they are confident it will
excellent year, up from 56%. have a positive impact on their business. This
• The expansionary approach to employment is particularly significant as the delay to its
which emerged during 2009 persists with a passage through Parliament was a major area of
majority of companies indicating they will frustration last year. Despite the Tax Incentive’s
increase staffing numbers in the coming year. The significantly changed provisions and the first
new positions will be predominately in ‘sales and claiming cycle already being well underway,
marketing’, ‘scientists and clinical trial staff’. 53% of companies had not yet sought
professional advice.
• Despite 54% of respondents raising capital during
2011, funding remains a significant industry • The majority of responding companies
issue with 34% indicating they have less than 12 (62%) are manufacturing. 46% of the overall
months cash on hand at current burn rates. 46% respondents are manufacturing in Australia
intend to raise capital in the coming year and a and a further 34% are manufacturing overseas.
further 20% are undecided. There is a crossover of 18% of companies
manufacturing both overseas and in Australia.
• The Australian operating environment (economic
and public policy) remains a concern, with only • Collectively the responding companies plan
24% of respondents identifying the environment to spend at least $610 million on research and
as conducive to growing a biotechnology development in 2012.
company, while 38% felt the environment was
neutral and 38% thought it was working against
the growth of companies.
02 April 2012
4. Background
At a glance Industry snap shot
AusBiotech’s representation and Australia continues to be a leading
promotion of the biotechnology location for biotechnology in The survey
industry continues to influence on the Asia-Pacific region and The survey results provide an
critical issues. the world, with the Australian independent perspective of the
biotech industry ranked the fifth impact of the current economic
While input on public policy and regulatory environment on
is a year-round and core part of most innovative in the world, by
Scientific American World View the biotechnology industry.
AusBiotech’s work, it’s vital to
formally seek views from the magazine (July 2011). With more Issues investigated include:
industry to get a comprehensive, than 400 biotechnology companies • Sentiment
updated picture of the Australian and 600 medtech companies, the • Funding
biotechnology industry from its Australian biotechnology industry
has performed strongly despite an • Government policy
leaders.
unpredictable economic market. AusBiotech and Grant
The annual Biotechnology Thornton would like to express
Industry Position Survey, The industry is characterised
by many small to medium private appreciation to those who
proudly supported by Grant participated in the survey in
Thornton, sought the views and public companies. There are
currently in-excess of 100 ASX- support of the industry.
of CEOs on the operating
environment, the industry, and listed life sciences companies:
how their companies are faring. almost 40 in medtech and more
than 60 in biotechnology.
The results enable evidence-
based statements about the The Australian industry has
magnitude of issues and trends and received a major boost with
what should be done in response the 2011 passing of the R&D
to them. Tax Incentive legislation. This
will inject significant new funds
At any given time there are a
for innovative biotechnology
raft of biotech-related issues and
companies and deliver spill-over
developments, where policy is
benefits for the community from
vital to the industry’s progression
biotechnologies.
and future.
Biotechnology Industry Position Survey 03
5. Survey findings - Sentiment
A number of good news items and sizeable deals
in the Australian biotechnology industry have
kept spirits high amid and despite the economic
gloom that has gripped the world.
Amongst the recent highlights, Acrux paid a $100 Optimistic outlook
million special dividend to its shareholders, after Optimism grew stronger with 82% (75%: 2011)
receiving its milestone payments from Axiron of respondents expect their business to grow in the
licensee Eli Lilly & Co. This dividend is without coming year.
precedent in Australian biotech. TB diagnostics This continues the positive sentiment of
company, Cellestis was acquired by Dutch firm respondents when reflecting on 2011. 68% of
Qiagen for $370 million. respondents identified 2011 (56%: 2010) as a good
Less than a week into the New Year, Bionomics or excellent year.
was able to announce a collaboration, research,
and licensing agreement with US-based Ironwood During 2012 do you expect your business to grow, remain
Pharmaceuticals, potentially worth up to US$345 stable or decrease?
million, to develop and commercialise its anti-
anxiety compound, BNC210. Grow
The annual capital raising figures for the
industry (BioShares 30 Dec 2011), saw $630 6% Remain stable
million raised in 2011, a 14% increase on 2010 Decrease
when $554 million was raised. Notable capital
raisings were made by Pharmaxis, Starpharma and
Phosphagenics.
12%
82%
04 April 2012
6. Expansionary employment strategies
Despite a recent spate of high-profile redundancies in the Employment intentions?
broader Australian economy, the overall employment
conditions remain strong. Expansionary sentiment from 4% 6%
the 2010 and 2011 surveys continued into 2012 with 58%
of companies expecting to increase staff numbers. The new 30%
positions will be in ‘sales and marketing,’ and ‘scientists and 36%
clinical trial staff’. 44%
48%
Economic and public policy environment
The Australian operating environment (economic and
public policy) remains a concern, with only 24% of
respondents identifying the environment as conducive to
70%
growing a biotechnology company and 38% indicating the 52% 52% 58%
environment was working against the industry. Despite this
poor result, this is an improvement on the previous year
when 13% felt the environment was conducive to growth
and 52% felt it was working against the industry.
2009 2010 2011 2012
Research and Development tax incentive Hire Remain stable Decrease
The passage of the R&D Tax Incentive was well received with
65% of respondents expecting it to have a positive impact on
their business.
Despite the significantly changed provisions and the first How would you describe the Australian operating environment?
claiming cycle being well underway, 53% of companies had
not yet sought professional advice. Of those companies, 50%
plan to get advice soon, 39% feel they don’t need it and 11%
were undecided.
2012 24% 38% 38%
Collectively the responding companies plan to spend at
least $610 million on research and development in 2012. To put
this into context, the national budget for medical research for
the NHMRC’s (National Health and Medical Research Centre) 2011 13% 52% 35%
Medical Research Endowment Account Australia’s largest
source of public medical research funding, is almost $750
million in 2011-121.
Conducive Unfavourable Neutral
Impact of the R&D tax legislation?
13%
22%
65% Favourable
Negligible
Undecided
1
Source: BioShares Edition 439 (30 Dec 2011)
Biotechnology Industry Position Survey 05
7. Survey findings - Funding
High profile commercial deals and industry
returns provided significant momentum as
we entered 2011. The reality was a year full
of extreme financial turbulence and market
volatility.
From an overall market perspective capital raised Sources of funding
from IPOs was significantly lower than the Our previous survey reported that 24% of
previous year despite a relatively good March companies were holding less than 12 months cash
quarter. The second half of 2011 was littered with and 58% were planning to raise capital during
aborted floats. The vast majority of new listings 2011. We are pleased to report, that despite what
ended the year below listing price. ultimately turned out to be a very difficult year,
However on a more positive note, the respective 54% of respondents were able to raise capital.
listings and raisings of international companies The majority of funding was raised via the
Bioniche Life Sciences (raising $12.5 million) and issuance of equity. Other sources of funding such
GI Dynamics (raising $80 million) provide further as debt instruments and government grants and
evidence of Australia’s ever-increasing international concessions were also significant.
biotechnology presence.
The industry also provided two of the top four
best performing S&P/ASX 200 companies; Sigma Did you raise capital during 2011?
Pharmaceuticals (1st) and Mesoblast (4th).
46%
54% Yes
No
06 April 2012
8. Funding requirements
The appetite and competition for capital in 2012 will again be
high with 34% of respondents indicating they have less than
12 months cash and 46% anticipating raising capital during the
current year.
Whilst there is no escaping the significant macro risks still
prevalent, the industry appears well placed to leverage the
benefits associated with a maturing profile.
Do you plan on raising capital during 2012?
34%
20%
46% Yes
No
Potentially
46%
Biotechnology Industry Position Survey 07
9. Survey findings - Government policy
associated with the development, manufacture
Federal concerns and exploitation of patents in the UK – and
CEOs were asked which issues concern them enhance the UK’s competitiveness globally.
most at a federal level and to name the thing they
want most from the Federal Government, to assist Greater quanta of targeted funding support
the industry. Among the major industry concerns Almost four years after the demise of the
and desired assistance, the themes of note were: Commercial Ready program, the industry is still
• Incentives for investment; seeking a replacement that would provide access
• A greater quanta of targeted funding to adequate-sized grants for commercialisation
support; and activities and clinical trials.
• Predictability in relation to policy and Despite the recent improved provisions for
programs. CA grants, industry CEOs feel “the quanta
applied to CA grants is still too small for fast
outcomes,” and needs to be raised to a more
realistic level, such as $5 million.
Incentives for investment
Access to capital remains the biggest issue for
the biotechnology industry. While programs Lack of a consistent and appropriate
such as the R&D Tax Incentive, the Innovation grant and assistance program specific
for the biotech sector.
Investment Fund (IIF) and Commercialisation
Australia (CA) grants all assist, there remains a gap
in terms of incentives for investors.
Bring back a co-investment scheme
similar to the axed Commercial Ready.
Provide tax incentives for investors in
biotechnology to hold their investment
for 12+ months.
More predictability
A major theme in CEOs’ comments was the
The industry (and innovation more generally) notion of stability, certainty and a plea to keep
would benefit greatly from incentives for investors support programs, and keep them predictable.
in the form of tax breaks. An incentive for Respondents asked for the maintenance of
investors in innovation-based companies to hold current policies, as the changing of “goal posts”
their investment for a minimum period would is disruptive, and disables companies from
have a beneficial impact. making reliable forecasts.
The Australian industry is also keen to emulate
a new UK Government initiative, known as the
Patent Box. It provides a preferential regime for Uncertainty around policy is disruptive
profits arising from patents, allowing companies and hinders fund-raising strategy.
to apply a 10% corporation tax rate to profits
attributed to UK patents.
The Patent Box is expected to encourage More certainty. More transparency.
companies to locate high-value jobs and activity Longer term policy horizons.
08 April 2012
10. Employee remuneration
The majority of respondents use share options Do you manufacture and if so where?
and shares in addition to cash to remunerate their
employees. Only 16% of companies remunerated
with cash alone.
Not surprisingly, the tax treatment of share
62%
options and shares was repeatedly cited as a barrier
to biotechnology companies in competing for and
retaining highly-skilled talent.
34%
Manufacturing
The majority of responding companies (62%) 18%
are manufacturing. 46% of overall respondents
are manufacturing in Australia and 34% are
46%
manufacturing overseas. There is a crossover of
18% where companies manufacture both overseas
and in Australia.
AusBiotech believes there is a serious lack
of understanding, at a policy level, about the
contribution that biotechnology and medical device
companies are making and can further make to
manufacturing in Australia, or what their needs or
barriers are – and in what ways they differ from the
38% Don’t manufacture
Manufacture
manufacturers of commoditised items, such as cars. Manufacture in Australia
Biotechnology is one of the so-called ‘sunrise Manufacture overseas
industries’ and fits neatly with the Government’s
desire to move to advanced manufacturing, Manufacture both
providing high value-added products, with highly-
skilled labour and global production chains, for
niche markets.
AusBiotech sees an opportunity for
manufacturers of medicines, medical devices and
diagnostics to become the rule not the exception.
Policy must support a future manufacturing
industry that will provide highly-skilled jobs and
excellent returns to the economy.
Biotechnology Industry Position Survey 09
11. Demographics
About the survey Analysis of respondents
This is the second joint Biotechnology Companies were asked to submit
Industry Position Survey by AusBiotech information regarding their financial
and Grant Thornton. The survey was status, issues impacting their business,
conducted via mail and email during their current outlook and expected plans
January 2012. It was open to all ASX- for the future.
listed life sciences companies and Responses were received from 50
AusBiotech member biotechnology companies; the major identified area
companies, including unlisted of business was Therapeutics (56%)
companies. with medical devices and diagnostics
Issues explored by the Biotechnology representing 26% and 20% respectively.
Industry Position Survey were identified
by AusBiotech and Grant Thornton’s
Life Sciences team. Enquiries regarding
this survey may be directed to:
Dr Anna Lavelle For additional copies of the survey, please contact
T + 61 3 9828 1404
E alavelle@ausbiotech.org
AusBiotech www.ausbiotech.org or Grant Thornton at
www.grantthornton.com.au
Lorraine Chiroiu
T + 61 3 9828 1414
E lchiroiu@ausbiotech.org
Michael Cunningham
T + 61 3 8663 6000
E michael.cunningham@au.gt.com
Brock Mackenzie
T + 61 3 8663 6273
E brock.mackenzie@au.gt.com
10 April 2012
12. Survey participants
Sincere thanks goes to the
following participations, who
agreed to be named.
• Acrux • Grey Innovation
• AIMEDICS • Hatchtech
• AMGEN • Hunter Immunology
• ASDM • Immune System Therapeutics
• AstraZeneca • ImpediMed
• Atomo Diagnostics • iNova Pharmaceuticals
• BioDiem • Invetech
• Bioplatforms Australia • Lipotek
• Bluechiip • Minomic International
• Broadvector • MyGene
• Cellmid • Neural Diagnostics
• Cell Therapies • Photonz Corporation
• Clinical Genomics • PolyActiva
• CSL • Prana Biotechnology
• Cyclopharm • Progen Pharmaceuticals
• Devro • Shire Australia
• Genera Biosystems • Sienna Cancer Diagnostics
• Genetic Technologies • Tissue Therapies
• Given Imaging • Viralytics
• GlaxoSmithKline
AusBiotech and Grant Thornton wish to thank the remaining survey
participants who did not wish to be named here.
Biotechnology Industry Position Survey 11
13. About AusBiotech
AusBiotech is Australia’s biotechnology
industry organisation, which represents over
3,000 members, covering the human health,
agricultural, medical devices and diagnostics,
functional foods, environmental and industrial
industries in biotechnology.
AusBiotech is dedicated to the development, growth and prosperity of
the Australian biotechnology industry, by providing initiatives to drive
sustainability and growth, outreach and access to markets, and representation
If you want to know
and support for members nationally and around the world. more, please contact
AusBiotech is a not-for-profit organisation, which has representation in each AusBiotech’s national
Australian state and in various special interest sectors. Active state committees
and advisory groups provide a national network to support members and office...
promote the commercialisation of Australian bioscience in the global AusBiotech
marketplace. 1/322 Glenferrie Road,
Malvern, VIC 3144
AusBiotech has been working on behalf of members for more than 25 years, T +61 3 9828 1400
since it was established as the Australian Biotechnology Association and 15 years E admin@ausbiotech.org
later changed its name to AusBiotech. W www.ausbiotech.org
AusBiotech’s membership base includes biotechnology companies, ranging
from start-ups to mature multinationals, research institutes and universities,
specialist service professionals, corporate, institutional, individual and student
members from Australia and overseas.
12 April 2012
14. About Grant Thornton Australia
Grant Thornton is one of the world’s leading
organisations of independent assurance, tax
and advisory firms.
We help dynamic organisations unlock their potential for growth by providing
specialist services, business advice and growth solutions. In Australia, we have If you want to know
more than 900 staff across five offices in Adelaide, Brisbane, Melbourne, Perth
and Sydney. We combine service breadth, depth of expertise and industry more, please contact us…
insight with an approachable “client first” mindset and a broad commercial
perspective. Adelaide Perth
Simon Gray Jeff Vibert
We are a member of Grant Thornton International which comprises firms T +61 8 8372 6666 T +61 8 9480 2000
E simon.gray@au.gt.com E jeff.vibert@au.gt.com
operating in more than 100 countries worldwide. Through this membership,
we access global resources and methodologies that enable us to deliver consistently Brisbane Sydney
high quality outcomes for owners and key executives in our clients. Cameron Smith Nicole Bradley
T +61 7 3222 0200 T 61 2 8297 2400
E cameron.smith@au.gt.com E nicole.bradley@au.gt.com
Matt Bell
T +61 7 3222 0266
E matt.bell@au.gt.com
Melbourne
Michael Cunningham
T +61 3 8663 6000
E michael.cunningham@au.gt.com
Brock Mackenzie
T +61 3 8663 6273
E brock.mackenzie@au.gt.com
Biotechnology Industry Position Survey 13
15. www.grantthornton.com.au
Grant Thornton Australia Limited is a member firm within Grant Thornton International Ltd. Grant Thornton International Ltd and the
member firms are not a worldwide partnership. Grant Thornton Australia Limited, together with its subsidiaries and related entities, delivers
its services independently in Australia. Liability limited by a scheme approved under Professional Standards legislation.